Literature DB >> 29452444

Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis.

F Nanne Croles1,2, Jaime Borjas-Howard2, Kazem Nasserinejad3, Frank W G Leebeek1, Karina Meijer2.   

Abstract

Antithrombin deficiency is a strong risk factor for venous thromboembolism (VTE), but the absolute risk of the first and recurrent VTE is unclear. The objective of this paper is to establish the absolute risks of the first and recurrent VTE and mortality in individuals with antithrombin deficiency. The databases Embase, Medline Ovid, Web of Science, the Cochrane Library, and Google Scholar were systematically searched for case-control and cohort studies. Bayesian random-effects meta-analysis was used to calculate odds ratios (ORs), absolute risks, and probabilities of ORs being above thresholds. Thirty-five publications were included in the systematic review and meta-analysis. Based on 19 studies, OR estimates for the first VTE showed a strongly increased risk for antithrombin deficient individuals, OR 14.0; 95% credible interval (CrI), 5.5 to 29.0. Based on 10 studies, meta-analysis showed that the annual VTE risk was significantly higher in antithrombin-deficient than in non-antithrombin-deficient individuals: 1.2% (95% CrI, 0.8-1.7) versus 0.07% (95% CrI, 0.01-0.14). In prospective studies, the annual VTE risk in antithrombin deficient individuals was as high as 2.3%; 95% CrI, 0.2-6.5%. Data on antithrombin deficiency subtypes are very limited for reliable risk-differentiation. The OR for recurrent VTE based on 10 studies was 2.1; 95% CrI, 0.2 to 4.0. The annual recurrence risk without long-term anticoagulant therapy based on 4 studies was 8.8% (95% CrI, 4.6-14.1) for antithrombin-deficient and 4.3% (95% CrI, 1.5-7.9) for non-antithrombin-deficient VTE patients. The probability of the recurrence risk being higher in antithrombin-deficient patients was 95%. The authors conclude that antithrombin deficient individuals have a high annual VTE risk, and a high annual recurrence risk. Antithrombin deficient patients with VTE require long-term anticoagulant therapy. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29452444     DOI: 10.1055/s-0038-1625983

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  6 in total

1.  Pulmonary Thromboembolism in Immune Thrombocytopenia: A Report of Five Cases and a Review of the Literature.

Authors:  Yong Tan; Min Yan; Zhen Cheng; Xiangtao Pan
Journal:  Int J Gen Med       Date:  2021-08-13

2.  Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia.

Authors:  Evelien Krumb; Cedric Hermans
Journal:  Res Pract Thromb Haemost       Date:  2021-02-17

3.  Missense mutation of SERPINC1 (p.Ser426Leu) in a young patient presenting as refractory and recurrent venous thromboembolism: A case report.

Authors:  Haixu Yu; Xiaoyan Gai; Jianli Wang; Jinman Zhuang; Wanwan Guo; Rui Qiao; Hong Zhu; Yongchang Sun
Journal:  Front Cardiovasc Med       Date:  2022-08-24

4.  Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower-leg injury or knee arthroscopy.

Authors:  Yassene Mohammed; Carolina E Touw; Banne Nemeth; Raymond A van Adrichem; Christoph H Borchers; Frits R Rosendaal; Bart J van Vlijmen; Suzanne C Cannegieter
Journal:  J Thromb Haemost       Date:  2022-01-06       Impact factor: 16.036

5.  Thrombophilia testing: A British Society for Haematology guideline.

Authors:  Deepa J Arachchillage; Lucy Mackillop; Arvind Chandratheva; Jayashree Motawani; Peter MacCallum; Mike Laffan
Journal:  Br J Haematol       Date:  2022-05-29       Impact factor: 8.615

Review 6.  Anticoagulant and signaling functions of antithrombin.

Authors:  Alireza R Rezaie; Hemant Giri
Journal:  J Thromb Haemost       Date:  2020-09-09       Impact factor: 16.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.